Because first-line treatment of HER2-positive disease includes chemotherapy combined with HER2-directed agents, one cannot distinguish whether the cancer is sensitive to chemotherapy or to the HER2-directed therapy; the combination is synergistic [2]. The gene discussed is ERBB2; the disease is cancer.